Evidence map›Paper›PMID 28740376›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2017

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.

A Papi, D Dokic, W Tzimas, I Mészáros, A Olech-Cudzik, Z Koroknai, K McAulay, S Mersmann, P S Dalvi, T Overend

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 5 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Race-Based Pulmonary Function Testing Correction in COPD Inhaler Therapy Trials: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Discordant diagnostic criteria for pneumonia in COPD trials: a review.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD.International journal of chronic obstructive pulmonary disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 7 countries.

A PapiDepartment of Internal and CardioRespiratory Medicine, Reseach Center on Asthma and COPD, University of Ferrara, Ferrara, Italy.
D DokicClinic of Pulmology and Allergy, Clinical Centre, Medical Faculty, Ss. Cyril and Methodius University, Skopje, Macedonia.
W TzimasPneumologische Praxis, München, Germany.
I MészárosCoral Szakorvosi Centrum, Budapest, Hungary.
A Olech-CudzikOstrowieckie Centrum Medyczne Spółka, Ostrowiec Swietokrzyski, Poland.
Z KoroknaiPAREXEL International, Global Medical Services, Budapest, Hungary.
K McAulayMedical Operations, Mundipharma Research Limited, Cambridge, UK.
S MersmannBiostatistics and Clinical Data Science, Mundipharma Research GmbH & Co. KG, Limburg, Germany.
P S DalviMedical Science - Respiratory, Mundipharma Research Limited, Cambridge, UK.
T OverendMedical Science - Respiratory, Mundipharma Research Limited, Cambridge, UK.
Mundipharma (United Kingdom) · GBAkademii Nauk Stosowanych im. Józefa Gołuchowskiego · PLCorvinus University of Budapest · HUMundipharma (Germany) · DEOrthopädische Praxis · DEPAREXEL International (United Kingdom) · GBPulmonary and Allergy Associates · USUniversity of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. PATIENTS AND

methodsCOPD patients with forced expiratory volume in 1 s (FEV

resultsIn total, 1,765 patients were randomized. There were fewer discontinuations with FP/FORM 500/20 µg (20.6%) and 250/10 µg (24.0%) compared with FORM (26.1%). None of the two FP/FORM doses reduced the moderate/severe exacerbation rate versus FORM (rate ratios [RR]: 0.93;

conclusionFP/FORM did not reduce exacerbation rates versus FORM. Numerical benefits were observed with FP/FORM 500/20 µg versus FORM for secondary variables, including lung function, EXACT exacerbations, SGRQ-C and EXACT-respiratory symptoms total and breathlessness scores. Few efficacy differences were evident between FP/FORM 250/10 µg and FORM. Pneumonia was more frequent in FP/FORM-treated patients, although the absolute difference was low. Adverse events were otherwise similar between treatments.

Indexed as

Adrenergic beta-2 Receptor AgonistsAdultAgedAndrostadienesBronchodilator AgentsDisease ProgressionDouble-Blind MethodDrug CombinationsEthanolaminesEuropeFemaleFluticasoneForced Expiratory VolumeFormoterol FumarateHumansLungAdrenergic beta-2 Receptor AgonistsAndrostadienesBronchodilator AgentsDrug CombinationsEthanolaminesFluticasonefluticasone-formoterolFormoterol Fumaratechronic bronchitisemphysemaeosinophilsexacerbationsflutiform

Identifiers

PMID28740376
PMCPMC5505160
OpenAlexW2725159734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.